Table 1 Patient characteristics

Entered

67

Age (years)

   Median (range)

62 years (range 39 – 83 y)

Estrogens receptor positive

62 (92.5%)

Progesterone receptor positive

42 (62.7%)

Her2 positive

10 (14.9%)

Adjuvant chemotherapy

27 (40.3%)

Adjuvant endocrine therapy

36 (53.7%)

Palliative chemotherapy

44 (65.7%)

Fulvestrant treatment

   1^st line

3 (4.5%)

   2^nd line

27 (40.3%)

   3^rd line

28 (41.8%)

   4^th line

9 (13.4%)

Prior endocrine treatment

   Tamoxifen

17 (25.4%)

   Anastrozole/Letrozole

59 (88.1%)

   Exemestane

32 (47.8%)

   MPA

1 (1.5%)

   Goserelin

1 (1.5%)

Metastatic sites

   Lung

19

   Liver

20

   Bones

44

   Lymph nodes

15

   Soft tissue

19

   Skin

10

   Other

1

More than one metastatic site

40 (59.7%)

Number of met. Sites

   Median (range)

2 (range 1 – 4)